Controlled research vocabulary
Research material, evidence and analytical terms—defined precisely.
A shared vocabulary for reading product specifications, Certificates of Analysis, research papers and evidence summaries without confusing unlike measurements or levels of evidence.
- 27
- defined terms
- 5
- topic groups
- 1
- shared vocabulary
Search the controlled vocabulary
Search by term or definition, or narrow the list by topic. Every entry has a permanent anchor suitable for linking from product and editorial pages.
Analytical method
A documented procedure used to measure identity, purity, assay, concentration or another material attribute.
A result is interpretable only when the method, sample preparation, system suitability and reporting basis are known.
Assay
A quantitative measurement of the amount or activity of the stated analyte relative to a defined basis.
Assay is not automatically the same as chromatographic purity, net peptide content or biological potency.
Certificate of Analysis (CoA)
A lot-linked record reporting selected test methods, specifications and results for a material.
A generic or example CoA cannot establish the release status of a different lot; the catalog number and lot number should match.
Chromatographic purity
The relative distribution of detected chromatographic peaks under a stated method, commonly reported as area percent.
Area percent depends on detection and method conditions and does not equal total mass fraction or net peptide content.
Counterion
An oppositely charged ion associated with an ionic molecule or peptide salt, such as acetate or trifluoroacetate.
Counterion identity and amount affect molecular-weight calculations, composition and sometimes solubility.
DAC (Drug Affinity Complex)
A reactive albumin-binding design used in the long-acting CJC-1295 material described in early human studies.
Evidence for the DAC form should not be assigned to a material marketed as “without DAC.”
Evidence boundary
The limit beyond which a cited study or record does not support a broader claim.
Species, population, intervention, formulation, route, endpoint and study design define what can and cannot be concluded.
Finished medicine
A manufactured dosage form supplied under defined formulation, quality, labeling and regulatory controls.
Approval or trial evidence for a finished medicine does not verify an unrelated research-use catalog material.
HPLC
High-performance liquid chromatography, a separation technique used to characterize components detected under a defined method.
An HPLC result needs method conditions and detection context; one percentage cannot establish identity or total composition by itself.
In vitro
Research performed outside a living organism, such as in cells, isolated tissues or biochemical systems.
In-vitro activity can support mechanism research but does not establish exposure, safety or effectiveness in a person.
Investigational
Under study and not established as an approved product or use in the regulatory context being discussed.
A clinical-development program, trial registration or sponsor announcement is not the same as regulatory approval.
LC-MS
Liquid chromatography coupled with mass spectrometry, combining separation with mass-to-charge measurement.
LC-MS can support identity and impurity characterization, but the stated ion, charge state and mass interpretation should be reported.
Lot / batch
A defined quantity of material produced or processed under a common manufacturing record and assigned a traceable identifier.
Release results apply to the identified lot; they should not be generalized to every past or future batch.
Molar mass
The mass of one mole of a defined chemical entity, normally expressed in grams per mole.
Calculations must use the stated sequence or chemical form and clarify whether salts, counterions, solvates or conjugates are included.
MS/MS
Tandem mass spectrometry, in which selected ions are fragmented and the product-ion pattern is measured.
Fragment information can provide stronger sequence or structural support than intact mass alone when properly interpreted.
Net peptide content
The estimated mass fraction attributable to peptide after accounting for water, counterions and other non-peptide components under a stated calculation.
It answers a different question from HPLC area purity and can materially affect mass-based calculations.
Nominal fill
The labeled or target quantity assigned to a container presentation rather than an independently displayed lot result.
A catalog size should not be described as a verified analytical result unless the applicable release document supports it.
Peptide analogue
A peptide intentionally modified from a reference or endogenous sequence to alter properties such as stability, binding or exposure.
Evidence for the reference peptide cannot automatically be transferred to the analogue, or vice versa.
Preclinical
Laboratory or animal research conducted before or outside confirmatory clinical evaluation in humans.
Preclinical findings support biological plausibility and model-specific questions, not clinical effectiveness.
Primary endpoint
The prospectively designated main outcome used to answer a study’s principal research question.
Secondary, exploratory and post-hoc findings should not be presented with the same evidentiary weight as a prespecified primary endpoint.
Randomized controlled trial (RCT)
A study in which participants are assigned to interventions by a random process and outcomes are compared under a defined protocol.
Randomization supports within-trial causal comparison; it does not make results from separate trials directly comparable.
Research-use material
A catalog material supplied for laboratory, development or manufacturing research rather than as a finished medicine.
Its identity and lot documentation must be evaluated independently from clinical products carrying a similar molecular name.
Residual solvent
A volatile organic chemical remaining from synthesis, purification or processing and measured against a stated method or limit.
Residual-solvent results are separate from peptide purity and should identify both the analytes and reporting limits.
Sponsor topline result
A high-level result announced by a study sponsor before a complete peer-reviewed report or full regulatory review is available.
It can update development status but usually lacks enough methodological detail for full independent appraisal.
System suitability
Predefined checks showing that an analytical system is performing adequately for the intended method before or during sample analysis.
A numerical result without acceptable system performance may not be reliable for release or comparison.
Variant
A distinct catalog presentation within one molecular product family, separated by identifier, pack size, concentration or composition.
Variants can share one canonical family page while retaining unambiguous quotation and lot-document references.
Water content
The amount of water measured in a material using a stated analytical procedure.
Water contributes to total sample mass and may affect net-content calculations, stability interpretation and storage controls.
No matching term
Try a broader word or reset the topic filter.
Interpretation workflow
Use definitions in the right order.
A quality term describes a material measurement. An evidence term describes what a study can support. A regulatory term describes a product or development status. Combining those categories into one claim creates avoidable ambiguity.
Sequence, chemical form, salt, counterion, conjugation and formulation.
Method, reporting basis, specification and lot-linked result.
Analytical, in-vitro, animal, human, regulatory or sponsor record.
Say what the cited result cannot establish for another material or context.
Apply the vocabulary